Radu Corina, Dejica Doru, Grigorescu Mircea, Zaharie Teodor, Neculoiu Daniela
"Iuliu Hatieganu" University of Medicine and Pharmacy, Str Croitorilor no 19-21, 3400 Cluj-Napoca, Romania.
Rom J Gastroenterol. 2003 Jun;12(2):91-5.
Intercellular cell adhesion molecules-1 (ICAM-1) and vascular cell adhesion molecules-1 (VCAM-1) are expressed in a high quantity on hepatocytes and at the level of endothelium cells from sinusoidal vessels in the liver tissue of patients with chronic hepatitis C. The soluble forms of these molecules sICAM-1 and sVCAM-1 can be determined in the serum of patients through the immunoenzymatic technique (ELISA).
of the study was to analyse the base level of these molecules and the changes induced through the combined treatment of interferon-alpha (IFN- alpha) and ribavirin (Rib).
Twenty patients suffering from viral chronic hepatitis C were studied: 10 patients responded completely to antiviral treatment and 10 patients showed no response at the end of the treatment. At the end of the therapy patients were placed under biochemical observation for a further six months. The serum concentration of sICAM-1 and sVCAM-1 was measured using ELISA assay at the beginning and the end of the combined treatment: six months IFN 3MU (three times a week) associated with Rib.
Statistically, a significant correlation was observed between the values of sICAM-1 pretreatment and the level of viremia, gamma glutamiltrans-peptidase (GGT), but without correlation to the alanin amino transferase (ALT) level. The value of sICAM-1 was significantly higher in patients who had fibrosis score F: 3-4. After the treatment, the serum concentration of sICAM-1 dropped significantly in patients with sustained biochemical response in comparison to patients who had an unsustained response or had no response whatsoever. A significant correlation between the sVCAM-1 pre-treatment value and the level of viremia, GGT, ALT was not established.
The level of sICAM-1 could be a useful parameter in the observation of the disease evolution of patients with viral chronic hepatitis C treated with IFN-alpha and Rib.
细胞间黏附分子-1（ICAM-1）和血管细胞黏附分子-1（VCAM-1）在慢性丙型肝炎患者肝组织的肝细胞及肝血窦内皮细胞水平大量表达。这些分子的可溶性形式sICAM-1和sVCAM-1可通过免疫酶技术（ELISA）在患者血清中检测到。
分析这些分子的基础水平以及α-干扰素（IFN-α）和利巴韦林（Rib）联合治疗引起的变化。
研究了20例慢性丙型病毒性肝炎患者：10例患者对抗病毒治疗完全有效，10例患者在治疗结束时无反应。治疗结束后，对患者进行了为期6个月的生化观察。在联合治疗开始和结束时，即6个月的IFN 3MU（每周3次）联合Rib治疗时，使用ELISA法测量sICAM-1和sVCAM-1的血清浓度。
统计学上，sICAM-1治疗前值与病毒血症水平、γ-谷氨酰转肽酶（GGT）之间存在显著相关性，但与丙氨酸氨基转移酶（ALT）水平无关。纤维化评分F为3-4的患者中sICAM-1值显著更高。治疗后，与未持续应答或无应答的患者相比，持续生化应答患者的sICAM-1血清浓度显著下降。未确定sVCAM-1治疗前值与病毒血症水平、GGT、ALT之间的显著相关性。
sICAM-1水平可能是观察接受IFN-α和Rib治疗的慢性丙型病毒性肝炎患者疾病进展的有用参数。
